The NHS could face a significant blow to its already stretched budget if Donald Trump returns to the White House, according to new analysis that warns of potential medicine shortages and soaring drug costs for British patients.
The Nuffield Trust, an independent health think tank, has raised concerns that a renewed "America First" approach could disrupt global pharmaceutical markets, leaving the UK vulnerable to supply chain pressures. With the NHS already grappling with substantial financial challenges, any sharp rise in medicine costs would put further strain on public finances at a time when healthcare budgets are under intense scrutiny.
The analysis highlights how deeply Britain depends on medicines manufactured in the United States or by companies with major American operations. Should a future Trump administration restrict exports to prioritise domestic supply, the UK could face both shortages and price increases for essential medications. This scenario becomes particularly worrying when considering that many life-saving drugs have limited alternative suppliers.
A "buy American" policy could create a perfect storm for international buyers, the report suggests. Increased domestic demand in the US, combined with potential export limitations, would likely drive up global medicine prices across the board. For the NHS, this could translate into difficult choices about which treatments to fund and potential delays in accessing new medications.
The implications for patients could be far-reaching. Higher pharmaceutical costs would force the government to either increase NHS spending – potentially at the expense of other public services – or make tough decisions about drug availability. While the Nuffield Trust stops short of predicting specific price rises, it emphasises how political decisions in major manufacturing nations can ripple through global supply chains with serious consequences.
The findings serve as a wake-up call for UK policymakers to strengthen the resilience of Britain's medicine supply chain. The NHS's ability to provide comprehensive care without crippling costs depends on preparing for potential shifts in international trade policy, particularly from key partners like the United States.